- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01329588
Periodical Presumptive Treatment for the Control of Gonococcal Infections Among Sex Workers
Periodical Presumptive Treatment of Gonorrhoea in Female Sex Workers: Impact on Prevalence of the Disease in Sex Workers and Their Clients
In the early years of the HIV epidemic in Africa, female sex workers (FSWs) were identified as a high-prevalence, high-incidence, core group among whom the extraordinary prevalence of other sexually transmitted infections (STIs) facilitated transmission of the virus to their clients, who then infected low-risk women not involved in the sex trade. In resource-poor settings, control of Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) among FSWs is difficult. The purpose of this study is to determine whether periodical antibiotic treatment (PAT) is effective in controlling these infections among West African FSWs.
The study is designed as a cluster-randomized double-blind placebo-controlled trial conducted in West Africa. The study population consists of "seaters" FSWs who work from their homes in well-defined areas. Clusters will be paired according to their size and demographic characteristics of FSWs and clients. Within each pair, one cluster will be randomly allocated to the intervention and the other to the placebo group.
At enrollment, participants will be interviewed, a pelvic examination performed, cervical swabs obtained for NG and CT polymerase chain reaction (PCR), and current cervicitis or vaginitis managed syndromically. Blood specimens will be obtained for HIV testing. All participants will be given free condoms and counseled on risk reduction.
Monthly follow-up will be conducted within FSW communities, alternating with clinic visits where cervical samples will be collected. Study drugs (azithromycin 1 g and ciprofloxacin 500 mg, and their identical placebos) will be distributed every month according to a predefined schedule: directly-observed intake of azithromycin at months 1, 4 and 7, and ciprofloxacin at months 2, 3, 5, 6, 8 and 9.
Data will be analyzed with SAS. The investigators will assess the time trends in NG and CT prevalence separately in both study groups using χ2-for-trend.
Study Overview
Status
Intervention / Treatment
Detailed Description
"Seaters" are older, more stable, better organized, and have a much higher prevalence of HIV infection than FSWs who roam the streets or part-time sex workers. These communities (from 3 to 114 FSWs per site) will be aggregated into 18 clusters (one cluster was composed of 1-10 FSW communities) based on geographical proximity. Over a one-year period, FSWs from these clusters presenting to dedicated clinics will be invited to participate. In addition, field workers will visit FSWs at home or at prostitution sites to provide information about the trial and seek participation.
Clusters will be paired according to their size and demographic characteristics of FSWs and clients. Within each pair, one cluster will be randomly allocated to the intervention and the other to the placebo group using pre-coded envelopes. With an average of 35 FSWs per cluster, the required number of cluster pairs is estimated at 8.7 to detect a 50% reduction in NG prevalence, assuming a baseline prevalence of 25%, 80% power and 5% alpha error.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Cotonou, Benin
- Dispensaire des infections sexuellement transmissibles
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female sex worker (seater) from one of the selected clusters
Exclusion Criteria:
- Allergy to study drugs
- Pregnancy
- Intention to leave the city within the next 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Sugar pill
|
Azithromycin placebo (sugar pill) per os once at months 1, 4 and 7 Ciprofloxacin placebo (sugar pill) per os once at months 2, 3, 5, 6, 8 and 9
|
Experimental: Treatment arm
|
Azithromycin 1g per os once at months 1, 4 and 7 Ciprofloxacin 500 mg per os once at months 2, 3, 5, 6, 8 and 9
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of gonococcal infection
Time Frame: 3 months
|
Cervical samples for NG PCR will be collected at the clinic visit planned at months 3 (between 45-134 days after enrolment).
Time trend in gonorrhoea prevalence will be analysed.
|
3 months
|
Presence of gonococcal infection
Time Frame: 6 months
|
Cervical samples for NG PCR will be collected at the clinic visit planned at months 6 (between 135-224 days after enrolment).
Time trend in gonorrhoea prevalence will be analysed.
|
6 months
|
Presence of gonococcal infection
Time Frame: 9 months
|
Cervical samples for NG PCR will be collected at the clinic visit planned at months 9 (between 225-315 days after enrolment).
Time trend in gonorrhoea prevalence will be analysed.
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of chlamydia infection
Time Frame: 3 months
|
Cervical samples for CT PCR will be collected at the clinic visit planned at months 3 (between 45-134 days after enrolment).
Time trend in gonorrhoea prevalence will be analysed.
|
3 months
|
Presence of chlamydia infection
Time Frame: 6 months
|
Cervical samples for CT PCR will be collected at the clinic visit planned at months 6 (between 135-224 days after enrolment).
Time trend in gonorrhoea prevalence will be analysed.
|
6 months
|
Presence of chlamydia infection
Time Frame: 9 months
|
Cervical samples for CT PCR will be collected at the clinic visit planned at months 9 (between 225-315 days after enrolment).
Time trend in gonorrhoea prevalence will be analysed.
|
9 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michel Alary, MD, PhD, Centre de recherche, Centre hospitalier affilié universitaire de Québec
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DR-002-947
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on Monthly placebo
-
University of TennesseeCompleted
-
University of California, IrvineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingChild Development | Brain Development | Household and Family ProcessesUnited States
-
Jordan University of Science and TechnologyCompletedOrthodontic ApplianceJordan
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedBurnout, Professional | Caregiver ExhaustionNetherlands
-
The University of Texas Health Science Center,...UnknownChildhood ObesityUnited States
-
Makerere UniversityBill and Melinda Gates FoundationCompleted
-
Colorado State UniversityNational Cancer Institute (NCI)RecruitingPhysical Activity Behavior | Behavior Change Interventions | Exercise OncologyUnited States
-
Northwestern UniversityNational Institutes of Health (NIH); Alzheimer's Association; Illinois Department... and other collaboratorsCompletedFrontotemporal Dementia | Primary Progressive AphasiaUnited States
-
EpicentreMédecins Sans Frontières, FranceCompleted
-
EpicentreCompletedSevere Acute MalnutritionNigeria